Cytodyn Inc (CYDY)

[Midasbro]

NEJM article: https://www.nejm.org/doi/pdf/10.1056/NEJMc2011117?listPDF=true

Although effective treatment of Covid-19 is currently unknown,2 immunosuppressive man- agement included withdrawal of an antimetabo- lite in 24 of 28 patients (86%). In addition, tacro- limus was withheld in 6 of the 28 severely ill patients (21%). Hydroxychloroquine was admin- istered to 24 of these 28 patients (86%). Apixa- ban was administered to patients with d-dimer levels higher than 3.0 µg per milliliter. Six severely ill patients received the CCR5 inhibitor leronlimab (PRO 140, CytoDyn) on a compassion- ate-use basis, and 2 received the interleukin-6 re- ceptor antagonist tocilizumab. Interleukin-6 levels were very elevated (range, 83 to 8175 pg per mil- liliter) when leronlimab was initiated (on day 0) in the 5 patients with elevated interleukin-6 lev- els; these levels decreased markedly 3 days later (range, 37 to 2022 pg per milliliter) (see Table S2 in the Supplementary Appendix). However, only the 1 patient who had the lowest interleukin-6 level (at 83 pg per milliliter) remained in stable condition without intubation.

Supplemental Table (page 7)

https://www.nejm.org/doi/suppl/10.1056/NEJMc2011117/suppl_file/nejmc2011117_appendix.pdf